Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
GLP-1 receptor agonists, the drug class that includes Ozempic, Wegovy, and Mounjaro, were originally developed to treat type 2 diabetes
Lose 14-15% of your body weight* *In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
Several professional societies and institutions have addressed the perioperative management of GLP-1RAs therapy to emphasize the potential risk of pulmonary aspiration and propose strategies for risk mitigation
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Turri Quarenghi, R
No customs hassles
US$ 28.51
US$ 26.12
US$ 27.27
